Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions-Reference-Cited by-同舟云学术

Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions

Published:2021-08-22 Issue:9 Volume:14 Page:819-830
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Cho Hee Jeong¹,Baek Dong Won¹,Kim Juhyung¹,Lee Jung Min¹,Moon Joon Ho¹,Sohn Sang Kyun¹

Affiliation:

1. Department of Hematology/Oncology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, South Korea

Publisher

Informa UK Limited

Subject

Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474086.2021.1967139

Reference98 articles.

1. Ibrutinib: A Review in Chronic Lymphocytic Leukaemia

2. MicroRNA-494 promotes cancer progression and targets adenomatous polyposis coli in colorectal cancer

3. Targeting Bruton's tyrosine kinase in B cell malignancies

4. Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

5. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL;Blood Advances;2024-06-03

2. Pharmacovigilance analysis of cardiac risks associated with Bruton tyrosine kinase inhibitors;Expert Opinion on Drug Safety;2023-04-19

3. Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities;Cancers;2023-02-27

4. Simultaneous Determination of Orelabrutinib, Zanubrutinib, Ibrutinib and Its Active Metabolite in Human Plasma Using LC-MS/MS;Molecules;2023-01-26

5. Amiodarone/aspirin/ibrutinib interaction;Reactions Weekly;2022-03